Mural Oncology plc (MURA)

NASDAQ: MURA · Real-Time Price · USD
3.380
+0.010 (0.30%)
At close: Nov 7, 2024, 4:00 PM
3.450
+0.070 (2.07%)
After-hours: Nov 7, 2024, 5:13 PM EST
0.30%
Market Cap 57.59M
Revenue (ttm) n/a
Net Income (ttm) -173.30M
Shares Out 17.04M
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,744
Open 3.330
Previous Close 3.370
Day's Range 3.330 - 3.420
52-Week Range 2.880 - 6.250
Beta n/a
Analysts Strong Buy
Price Target 16.00 (+373.37%)
Earnings Date Nov 19, 2024

About MURA

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 117
Stock Exchange NASDAQ
Ticker Symbol MURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MURA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 373.37% from the latest price.

Price Target
$16.0
(373.37% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune ac...

8 hours ago - GlobeNewsWire

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...

3 days ago - GlobeNewsWire

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...

4 weeks ago - GlobeNewsWire

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

6 weeks ago - GlobeNewsWire

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program

2 months ago - GlobeNewsWire

Mural Oncology to Present at Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

2 months ago - GlobeNewsWire

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025

3 months ago - GlobeNewsWire

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...

3 months ago - GlobeNewsWire

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

5 months ago - GlobeNewsWire

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expect...

6 months ago - GlobeNewsWire

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

7 months ago - GlobeNewsWire

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance wit...

7 months ago - GlobeNewsWire

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2...

8 months ago - GlobeNewsWire

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed...

8 months ago - GlobeNewsWire

Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value

Mural Oncology trades at approximately $5, a material discount to cash holdings of over $16/share, as reported in November 2023. The pipeline of 3 major candidates of cytokine cancer therapies at diff...

8 months ago - Seeking Alpha

Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference

DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed ...

9 months ago - GlobeNewsWire